{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:21Z","timestamp":1761870741936,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100021138","name":"Lundbeck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021138","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2015.03.002","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T18:46:33Z","timestamp":1430592393000},"page":"303-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"15","author":[{"given":"Carolyn","family":"Owen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bence-Bruckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e8s","family":"Chamakhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Toze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"Assaily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Christofides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.03.002_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.23491","article-title":"Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment","volume":"88","author":"Hallek","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.03.002_bib2","unstructured":"Canadian Cancer Society. Chronic Lymphocytic Leukemia. Available at: http:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/leukemia-chronic-lymphocytic-cll\/statistics\/?region=on. Accessed September 3,\u00a02014."},{"key":"10.1016\/j.clml.2015.03.002_bib3","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.leukres.2009.06.013","article-title":"High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort","volume":"33","author":"Seftel","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.03.002_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3324\/haematol.2012.069369","article-title":"Clinical implications of the molecular genetics of chronic lymphocytic leukemia","volume":"98","author":"Foa","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.03.002_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrclinonc.2010.167","article-title":"Prognostic factors in chronic lymphocytic leukemia-what do we need to know?","volume":"8","author":"Cramer","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2015.03.002_bib6","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.03.002_bib8","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.03.002_bib10","unstructured":"Health Canada. Patent register - form IV summaries for 02241927. Rituxan Submission No: 127356 Din: 02241927 NOC Date: August 7,\u00a02009."},{"key":"10.1016\/j.clml.2015.03.002_bib11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.leukres.2013.05.004","article-title":"Fludarabine: a review of the clear benefits and potential harms","volume":"37","author":"Lukenbill","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.03.002_bib12","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/cncr.28318","article-title":"Myelosuppression after front-line fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia","volume":"119","author":"Strati","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.03.002_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdp297","article-title":"The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy","volume":"21","author":"Gill","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.03.002_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428190802688517","article-title":"Treatment of elderly patients with chronic lymphocytic leukemia","volume":"50","author":"Eichhorst","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.03.002_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.03.002_bib16","unstructured":"New Evidence Perspectives in Oncology. Johnston J. Effective and better tolerated treatment options in CLL. Available at: http:\/\/www.newevidence.com\/oncology\/entries\/Effective_and_Better_Tolerated_Perspective\/. Accessed September 3, 2014."},{"key":"10.1016\/j.clml.2015.03.002_bib17","unstructured":"Leukemia and Lymphoma Society. Chronic Lymphocytic Leukemia. 2011. Available at: http:\/\/www.lls.org\/content\/nationalcontent\/resourcecenter\/freeeducationmaterials\/leukemia\/pdf\/cll.pdf. Accessed September 3, 2014."},{"key":"10.1016\/j.clml.2015.03.002_bib18","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/10428190701882955","article-title":"Molecular diagnostics in chronic lymphocytic leukemia \u2013 pathogenetic and clinical implications","volume":"49","author":"Zenz","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.03.002_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2013.1.158","article-title":"Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers","volume":"2013","author":"Shanafelt","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2015.03.002_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3747\/co.19.1064","article-title":"A\u00a0Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"19","author":"Van der Jagt","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2015.03.002_bib21","unstructured":"New Evidence Perspectives in Oncology. Stewart DA, Chen C, Sehn LH, Shustik\u00a0C. A Canadian Perspective on the Management of Chronic Lymphocytic Leukemia. Available at: http:\/\/www.newevidence.com\/oncology\/entries\/A_Canadian_Perspective_on_the_Management_of_Chr\/. Accessed September 3, 2014."},{"key":"10.1016\/j.clml.2015.03.002_bib22","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.03.002_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","article-title":"Fludarabine: a new agent with major activity against chronic lymphocytic leukemia","volume":"74","author":"Keating","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.03.002_bib25","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.03.002_bib26","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib27","first-page":"CD004270","article-title":"Purine antagonists for chronic lymphocytic leukaemia","author":"Steurer","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2015.03.002_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.536.536","article-title":"Long-term survival analysis of the North American Intergroup study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL)","volume":"114","author":"Rai","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib29","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3747\/co.21.1855","article-title":"A\u00a0Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events","volume":"21","author":"Koolwine","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2015.03.002_bib31","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.03.002_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","article-title":"Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial","volume":"159","author":"Knauf","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.03.002_bib33","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"year":"2014","series-title":"IMBRUVICA (Ibrutinib)","key":"10.1016\/j.clml.2015.03.002_bib34"},{"key":"10.1016\/j.clml.2015.03.002_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.03.002_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Mohammed","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.03.002_bib37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib38","unstructured":"Raiti L, Raj S, Carney D, et\u00a0al. Skin cancers are common and cause considerable morbidity in patients treated with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukaemia. 19th Congress of the European Hematology Association (EHA). 2014 (abstract 4832)."},{"key":"10.1016\/j.clml.2015.03.002_bib39","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood.V122.21.4181.4181","article-title":"Response to 1st-line treatment with BR or FCR in patients with chronic lymphocytic leukaemia: first outcome data from the german prospective TLN registry","volume":"122","author":"Knauf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.03.002_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428194.2011.605188","article-title":"Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials","volume":"53","author":"Gerrie","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.03.002_bib43","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"journal-title":"ASH Annual Meeting Abstracts","year":"2013","author":"Eichhorst","key":"10.1016\/j.clml.2015.03.002_bib44"},{"journal-title":"ASH Annual Meeting Abstracts","year":"2014","author":"Eichhorst","key":"10.1016\/j.clml.2015.03.002_bib45"},{"key":"10.1016\/j.clml.2015.03.002_bib46","unstructured":"Alberta Health Services. Clinical Practice Guideline LYHE-007. Chronic Lymphocytic Leukemia. Available at: http:\/\/www.albertahealthservices.ca\/hp\/if-hp-cancer-guide-lyhe007.pdf. Accessed February 1,\u00a02015."},{"key":"10.1016\/j.clml.2015.03.002_bib47","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/bcj.2013.32","article-title":"Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model","volume":"3","author":"Decaup","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2015.03.002_bib48","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3109\/10428191003717746","article-title":"The future of CD20 monoclonal antibody therapy in B-cell malignancies","volume":"51","author":"Czuczman","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.03.002_bib49","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in\u00a0vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2015.03.002_bib50","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"year":"2014","series-title":"Arzerra (ofatumumab) [product monograph]","key":"10.1016\/j.clml.2015.03.002_bib51"},{"key":"10.1016\/j.clml.2015.03.002_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.528.528","article-title":"Ofatumumab\u00a0+ chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911)","volume":"122","author":"Hillmen","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501500107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501500107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:01Z","timestamp":1761870421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501500107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S215226501500107X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.03.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}